La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Quanex Building Prods a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Quanex Building Prods..

Quanex Building Prods (NYSE:NX) Azioni, Catena delle Opzioni

Quanex Building Prods

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.

Quanex Building Products Corporation Common Stock

Quanex Building Products Corp

NEXTAGE Co Ltd

Nuveen California Select Tax-Free Income Portfolio Common Stock

Nuveen CA Select Tax Free Income Port

Lifull Co Ltd

NEXTDC LTD BRIS QLD ORD by NEXTDC Ltd, Brisbane QLD

Nextdc Ltd

NexPoint Diversified Real Estate Trust Common Stock

NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust 5.50% Series A Cumulative Preferred Shares ($25.00 liquidation preference per share)

NexGen Energy Ltd

NEXIEN BIOPHARMA INC by Nexien BioPharma, Inc.

Nexien BioPharma Inc

Next 15 Group PLC

NEXT 15 GROUP PLC U/ADR by NEXT 15 GROUP PLC

NXG NextGen Infrastructure Income Fund Common Shares of Beneficial Interest

Cushing® NextGen Infrastructure Income Fund

NxGen Brands Inc

NEXGOLD MINING CORP by Nexgold Mining Corp

NeXGold Mining Corp

NexGel Inc

NexGen Mining Inc

NEXTGEN HEALTHCARE INC COM

Next PLC

NEXT GROUP PLC UNSP/ADR by Next Group Plc

NEXTELIGENT HOLDINGS INC by Nexteligent Holdings Inc.

Nexteligent Holdings Inc

NEXT HYDROGEN SOLUTIONS by Next Hydrogen Solutions Inc.

Next Hydrogen Solutions Inc

Nuveen New Jersey Qualified Municipal Fund

Nuveen New Jersey Quality Municipal Income Fund

Nexalin Technology Inc

NEXLIVING CMNTYS INC by NEXLIVING CMNTYS INC.

Nuix Ltd

NEXT MEATS HLDGS INC by NEXT MEATS HLDGS INC.

Next Meats Holdings Inc

NextMart Inc

Nuveen New York Select Tax-Free Income Portfolio Common Stock

Nuveen NY Select Tax-Free Income Port

NORTHX NICKEL CORP by NORTHX NICKEL CORP.

NorthX Nickel Corp

NEXEON MEDSYSTEMS INC by Nexeon Medsystems Inc

NEXSCIENT INC by NEXSCIENT INC.

NextNav Inc

NEXOPTIC TECHNOLOGY CORP by NexOptic Technology Corp

NexOptic Technology Corp

Nuveen Select Tax Free Income Portfolio Common Stock

Nuveen Select Tax Free Income Portfolio

NTL EXPRESS GROUP PLC by National Express Group Plc.

Mobico Group PLC

NATIONAL EXPRESS GP U/ADR by National Express Group Plc.

NXP Semiconductors NV

NextPlat Corp

NEXANS PARIS ACT (FRANCE) by Nexans Paris ACT

Nexans

NEXPRISE INC by NexPrise, Inc.

NEXPOINT CAP INC A by NEXPOINT CAPITAL, INC.

NEXTERA ENTERPRISES INC A by Nextera Enterprises, Inc.

NXRA - United States Dollar

NexPoint Residential Trust, Inc. Common Stock

NexPoint Residential Trust Inc

Nexus

Next Science Ltd

Nexus Gold Corp Class A

Nexus Gold Corp

NEXIS INTL INDUS INC by Nexis International Industries, Inc.

Nexis International Industries Inc

NEXTECH SOLUTIONS INC by NexTech Solutions, Inc.

Nextech Solutions Inc

NEXT VISION STABILIZD SYS by NEXT VISION STABILIZED SYS

Next Vision Stabilized Systems Ltd

Nexstar Media Group Inc

NEXTracker Inc

NEXT BIOMETRICS GRP ORD by Next Biometrics Group AS

Next Biometrics Group ASA

NextCure Inc

Investment Managers Series Trust II AXS Green Alpha ETF

NEXTRACTION ENERGY CORP by Nextraction Energy Corp.

Nextraction Energy Corp

First Trust Indxx NextG ETF

NXT NUTRITIONALS HLDG INC by NXT Nutritionals Holdings, Inc.

NXT Nutritionals Holdings Inc

Simplify Exchange Traded Funds Simplify Next Intangible Core Index ETF

Next10 Inc

Nexstim Oyj

NEXTPLAY TECHS INC by NextPlay Technologies, Inc.

NextPlay Technologies Inc

Next Technology Holding Inc. - Ordinary Shares

Next Technology Holding Inc

Lifeist Wellness Inc

Simplify Exchange Traded Funds Simplify Next Intangible Value Index ETF

NEXITY FINANCIAL CORP by Nexity Financial Corp.

Nexity Financial Corp

Nxu Inc

Nexity SA

Benchmark analyst Reuben Garner reiterates Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) with a Buy and maintains $38 price target.

News

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Buy on Quanex Building Prods, Maintains $38 Price Target

Quanex Building Products (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nx#NYSE">NX</a>) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.70 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 4.29%. A quarter ago, it was expected that this housing materials maker would post earnings of $0.53 per share when it actually produced earnings of $0.66, delivering a surprise of 24.53%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Quanex, which belongs to the Zacks Building Products - Miscellaneous industry, posted revenues of $280.35 million for the quarter ended July 2024, surpassing the Zacks Consensus Estimate by 0.84%. This compares to year-ago revenues of $299.64 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Quanex shares have lost about 17.3% since the beginning of the year versus the S&amp;P 500&#39;s gain of 15.7%.
<h2>What&#39;s Next for Quanex?</h2>
While Quanex has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Quanex: mixed. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.79 on $289 million in revenues for the coming quarter and $2.33 on $1.07 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products - Miscellaneous is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
RPM International (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rpm#NYSE">RPM</a>), another stock in the broader Zacks Construction sector, has yet to report results for the quarter ended August 2024.
This specialty chemicals company is expected to post quarterly earnings of $1.76 per share in its upcoming report, which represents a year-over-year change of +7.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
RPM International&#39;s revenues are expected to be $2.02 billion, up 0.3% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2332431/quanex-building-products-nx-q3-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2332431">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Small Cap

Markets

Trading Ideas

Quanex Building Products Q3 Earnings and Revenues Beat Estimates

U.S. stocks were mixed, with the Nasdaq Composite falling around 150 points on Friday.
Shares of Quanex Building Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) rose sharply during Friday's session after the company reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/NX/earnings">FY24 guidance above estimates.</a>
Quanex Building Prods reported quarterly earnings of 73 cents per share which beat the analyst consensus estimate of 70 cents per share. The company reported quarterly sales of $280.300 million which beat the analyst consensus estimate of $278.457 million.
Quanex Building Products shares jumped 19.9% to $29.80 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) gained 28.4% to $91.64 after the company reported better-than-expected second-quarter financial results.</li>
<li>Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares rose 15.3% to $11.45 after the company announced it that the FDA has granted full approval to FILSPARI to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Also, HC Wainwright &amp; Co maintained a Buy rating on the stock and raised its price target from $20 to $23.</li>
<li>Zumiez Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) rose 15.3% to $29.67 following quarterly results.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) gained 15% to $44.58 after the company reported better-than-expected quarterly financial results and raised its FY25 guidance.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) gained 14.6% to $1.6050.</li>
<li>Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose 13.9% to $163.94 after the company reported better-than-expected quarterly financial results. Also, Oppenheimer and Baird maintained an Outperform rating on the stock and raised their respective price targets.</li>
<li>Bowlero Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) climbed 13.5% to $12.25 after the company reported better-than-expected fourth-quarter sales results and issued FY25 revenue guidance above estimates.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 9.7% to $1.4485.</li>
<li>Smartsheet Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) rose 9.6% to $54.11 following better-than-expected quarterly financial results. The company also raised its FY25 EPS outlook.</li>
<li>Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) gained 6.8% to $76.75 after the company reported better-than-expected quarterly adjusted EPS results. Also, the company authorized an additional $100 million of shares for repurchase.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 6% to $5.14 after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $5.30 to $8.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40748814/top-4-financials-stocks-that-may-crash-this-month">Top 4 Financials Stocks That May Crash This Month</a></li>
</ul>

Intraday Update

Movers

BOWL

GWRE

PACB

PSNY

SMAR

TVTX

ZUMZ

Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday

WIIM

Quanex Building Products shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

Shares of Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/quote/AGX/earnings">second-quarter financial results.</a>
Argan reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of 92 cents per share. The company reported quarterly sales of $227.015 million which beat the analyst consensus estimate of $183.550 million.
Argan shares jumped 18.4% to $84.54 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Wheeler Real Estate Investment Trust, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) gained 175.8% to $11.42 in pre-market trading after jumping 302% on Thursday.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) rose 52.3% to $1.23 in today's pre-market trading after the company announced it entered into a business agreement with CrossVision for joint entertainment offerings.</li>
<li>Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) gained 27.3% to $1.05 in the pre-market trading session. Vor Bio releaseD new clinical data confirming the effectiveness of shielded transplants for delivering targeted therapies.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 24.8% to $6.52 in pre-market trading after the company announced $30 million in financing commitments from the Middle East, the United States, and Asia.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 17.3% to $0.2135 in pre-market trading after jumping over 26% on Thursday.</li>
<li>Bowlero Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOWL#NYSE">BOWL</a>) shares gained 14.9% to $12.40 in pre-market trading after the company posted strong quarterly sales.</li>
<li>Meiwu Technology Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) gained 13.6% to $0.92 in pre-market trading.</li>
<li>Quanex Building Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) gained 8.6% to $27.00 in pre-market trading r after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose 6.4% to $153.11 in pre-market trading after the company reported better-than-expected fourth-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) fell 20.1% to $0.9349 in pre-market trading after jumping 63% on Thursday. Inspire Veterinary Partners recently signed a non-binding letter of intent (LOI) to acquire AI platform Vetaie.ai in an all-stock transaction.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) shares fell 19.8% to $1.01 in pre-market trading. Hoth Therapeutics shares surged 81% on Thursday after the company announced data from the treatment of epidermal growth factor receptor inhibitor associated papulopustular eruptions with its novel therapeutic HT-001.</li>
<li>Eastside Distilling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) shares fell 17.4% to $1.19 in pre-market trading after jumping 89% on Thursday. Eastside Distilling announced a $0.4 million registered direct offering, priced at a premium to market under Nasdaq rules.</li>
<li>Clene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares declined 17.4% to $5.21 in pre-market trading after falling 5% on Thursday.</li>
<li>ThredUp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) shares declined 16.1% to $0.73 in pre-market trading.</li>
<li>Autozi Internet Technology (Global) Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) fell 12.2% to $1.59 in pre-market trading after dipping 35% on Thursday.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 10.5% to $0.4743 in today's pre-market trading after dipping 18% on Thursday.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) shares fell 9.7% to $2.24 in pre-market trading after the company posted downbeat quarterly sales.</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares dipped 9.4% to $138.51 in pre-market trading. Broadcom reported better-than-expected third-quarter financial results after the closing bell on Thursday. The company said it expects fourth-quarter revenue of approximately $14 billion.</li>
<li>Smith &amp; Wesson Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) declined 8.7% to $12.96 in pre-market trading after the company reported worse-than-expected first-quarter financial results on Thursday.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

Pre-Market Outlook

AVGO

BLMZ

CLNN

EAST

FFIE

HOTH

SIFY

SWBI

TDUP

WHLR

Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Guidance

Quanex Building Products Says Prior Guidance For FY24 Is No Longer Valid; Now Expects Net Sales $1.275B-$1.285B Vs $1.074B Est.

Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.70 by 4.29 percent. The company reported quarterly sales of $280.300 million which beat the analyst consensus estimate of $278.457 million by 0.66 percent. This is a 6.45 percent decrease over sales of $299.640 million the same period last year.

Quanex Building Prods Q3 2024 Adj. EPS $0.73 Beats $0.70 Estimate, Sales $280.300M Beat $278.457M Estimate

Teleios Capital Partners GMBH Reports 9.8% Stake In Quanex Building Products As Of August 1; Says Will Seek To Increase Shareholder Value By Entering Into Future Dialogue With Quanex Building Products Management

ALLE

ROCK

UFPI

Shares of construction and building product companies are trading higher after store sales of building material and garden supplies rose 1.4% in June.

<a href="https://www.globenewswire.com/Tracker?data=6Pam9ovsax0AZvYmkPR33FD68lTg0QWQxOuC9AlNlEcwOX7LQhsMt8FOMN6Rfp-TLFSnfIQWv_nKv0hKZgNZKRldhLALiq4MXx4DgjnVvvmtCHwG1i6K45VbIoqb3Hmc">Quanex Building Products Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) ("Quanex" or the "Company") today announced that shareholders of both Quanex and Tyman plc (LSE:TYMN) ("Tyman") have approved Quanex's proposed acquisition of Tyman.
The acquisition remains subject to the satisfaction of customary closing conditions and is expected to close in August of this year.

Quanex Building Products' Acquisition Of Tyman Approved By Each Companies' Shareholders, Expected To Close In August Of This Year

Quanex Building Products Reaffirms FY24 Net Sales ~$1.1B Vs $1.090B Est.

Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.53 by 24.53 percent. The company reported quarterly sales of $266.200 million which beat the analyst consensus estimate of $262.950 million by 1.24 percent. This is a 2.68 percent decrease over sales of $273.535 million the same period last year.

Quanex Building Prods Q2 2024 Adj EPS $0.66 Beats $0.53 Estimate, Sales $266.200M Beat $262.950M Estimate

Quanex Building Products Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) has reached an agreement to acquire the entire issued and to be issued&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38350796/quanex-building-products-to-acquire-tyman-creating-a-comprehensive-solutions-provider-in-the-build" rel="noreferrer noopener">share capital of&nbsp;Tyman plc&nbsp;for about $1.1 billion enterprise value</a>,
Tyman offers solutions in the window and door hardware, commercial access solutions, and seals and extrusions vertical segments for residential and commercial users across its North America, U.K. and Ireland, and International divisions.
&#8220;This transformative acquisition accelerates our journey to becoming &#8216;BIGGER&#8217;, creating a leading supplier of building products with a more diverse geographic footprint, product offering and customer base,&#8221; said Chairman, President and CEO George Wilson.
&#8220;As one company, we will have an enhanced financial profile grounded in attractive margins, strong free cash flow and a healthy balance sheet, that will enable us to invest in organic and inorganic growth opportunities to deliver superior returns for investors.&#8221;
Under the agreement, Tyman shareholders will be entitled to receive an implied value of 400.0 pence for each Tyman share based on Quanex&#8217;s last closing share price of $34.64 on April 19, 2024.
Tyman shareholders will have the option to elect to receive the consideration as either a mix of 240.0 pence in cash and 0.05715 shares of Quanex common stock for each Tyman share, or as a capped all-share alternative of 0.14288 shares of Quanex common stock per Tyman share.
The acquisition is expected to be meaningfully accretive to earnings in the first full fiscal year following the completion, taking into account cost synergies.
Upon closure, Tyman shareholders will own between approximately 30% and 32% of Quanex, depending on shareholder elections.
Tyman shareholders will also be approved to get the final dividend of 9.5 pence per Tyman share, as declared by Tyman on March 7, 2024.
The acquisition is expected to close in the second half of calendar year 2024. Quanex held $44.4 million in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37546313/quanex-building-products-announces-first-quarter-2024-results-and-provides-full-year-2024-guidance" rel="noreferrer noopener">cash and equivalents as of January 31, 2024</a>.
Price Action: NX shares closed higher by 1.17% at $34.64 on Friday.
Image sourced from Shutterstock

General

Quanex Makes Billion-Dollar Move: Acquires Construction Solution Provider Tyman

<ul>
<li>Acquisition Accelerates Quanex&#39;s &quot;BIGGER&quot; Strategic Roadmap, Expanding Quanex&#39;s Product Offering with Addition of Tyman&#39;s Complementary Portfolio</li>
<li>Significantly Enhances Scale and Global Reach, Positioning Combined Company&nbsp;for Profitable Growth and Value Creation</li>
<li>Delivers Material EPS Accretion in First Fiscal Year Post Close;</li>
<li>Approximately&nbsp;$30 Million&nbsp;in Annual Run-Rate Cost Synergies Anticipated</li>
</ul>

Quanex Building Products Agrees To Acquire Tyman For $1.1B, Enhancing Building Products Offerings

Benchmark analyst Reuben Garner maintains Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) with a Buy and raises the price target from $35 to $38.

Benchmark Maintains Buy on Quanex Building Prods, Raises Price Target to $38

Quanex Expects FY24 Net Sales Of ~$1.1B vs $1.09B Est.

Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) reported its Q1 earnings results on Thursday, March 7, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Quanex Building Prods beat estimated earnings by 64.0%, reporting an EPS of $0.18 versus an estimate of $0.11.
Revenue was down $22.76 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.25 which was followed by a 11.0% drop in the share price the next day.
Here's a look at Quanex Building Prods's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.65</td>
<td>0.41</td>
<td>0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.95</td>
<td>0.97</td>
<td>0.66</td>
<td>0.18</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>291.01M</td>
<td>289.28M</td>
<td>270.43M</td>
<td>261.89M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>295.49M</td>
<td>299.64M</td>
<td>273.54M</td>
<td>261.92M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Quanex Building Prods <a href="https://www.benzinga.com/quote/NX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Quanex Building Prods Q1 Earnings

Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) reported quarterly earnings of $0.180 per share which beat the analyst consensus estimate of $0.110 by 63.64 percent. The company reported quarterly sales of $239.155 million which beat the analyst consensus estimate of $231.428 million by 3.34 percent. This is a 8.69 percent decrease over sales of $261.916 million the same period last year.

Quanex Building Prods Q1 2024 Adj EPS $0.180 Beats $0.110 Estimate, Sales $239.155M Beat $231.428M Estimate

Allspring Special Small Cap Value Fund Q2 2024 Quarterly Review

Quanex Building Products Non-GAAP EPS of $0.73 beats by $0.02, revenue of $280.3M beats by $1.69M

Quanex Building Products Corporation (NX) Q3 2024 Earnings Call Transcript

50 stocks that may see selling pressure as investors begin looking to book tax losses

Warning: NX is at high risk of performing badly

Benchmark Co. analyst Reuben Garner reiterated a Buy rating on Quanex (NX – Research Report) today and set a price target of $38.00. The company's ...

Comments

Quanex Building Prods

Quanex Building Prods (NX) Opzioni

Quanex Building Prods (NYSE:NX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO